NASDAQ:BDSI - BioDelivery Sciences International Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.82 +0.19 (+4.10 %)
(As of 02/20/2019 06:55 AM ET)
Previous Close$4.63
Today's Range$4.65 - $4.95
52-Week Range$1.70 - $4.95
Volume896,550 shs
Average Volume485,426 shs
Market Capitalization$341.30 million
P/E Ratio-12.36
Dividend YieldN/A
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BDSI



Sales & Book Value

Annual Sales$61.99 million
Book Value$0.16 per share


Net Income$5.28 million


Market Cap$341.30 million

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings data on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The specialty pharmaceutical company earned $12.18 million during the quarter, compared to analysts' expectations of $12.44 million. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for BioDelivery Sciences International.

What price target have analysts set for BDSI?

4 Wall Street analysts have issued 1 year price targets for BioDelivery Sciences International's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.75 in the next year. This suggests that the stock has a possible downside of 1.5%. View Analyst Price Targets for BioDelivery Sciences International.

What is the consensus analysts' recommendation for BioDelivery Sciences International?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. Cantor Fitzgerald analysts commented, "We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00." (2/8/2019)
  • 2. According to Zacks Investment Research, "BioDelivery secured improved positioning in several managed care contracts providing preferred access to Belbuca. The company’s efforts has brought 100 million patients under preferred coverage so far this year, having started the year with 7 million. This has already started to boost the drug’s sales and profitability in 2018. Belbuca’s prescriptions has grown sequentially every quarter in 2018.  Increase in sales force has supported the growth. BioDelivery’s shares have outperformed the industry in the past six months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market. Estimates have remained stable ahead of Q4 earnings. BioDelivery has a positive record of earnings surprises in the recent quarters." (1/23/2019)
  • 3. HC Wainwright analysts commented, "Our $5, 12-month price target is based on a DCF reflecting strong Belbuca growth to over $150M by 2022, cash- flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10.5% WACC discount and negative -15% terminal value beyond 2027, and includes 93M shares (post-financing, plus other currently anti-dilutive shares)." (11/2/2018)

Has BioDelivery Sciences International been receiving favorable news coverage?

Media stories about BDSI stock have been trending somewhat positive on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Mr. Ernest Robert De Paolantonio CPA, MBA, CFO & Treasurer (Age 65)
  • Mr. Herm Cukier, CEO & Director (Age 52)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
  • Mr. Joseph M. Lockhart, Sr. VP of Operations
  • Ms. Mary Coleman, VP of Investor & PR

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by many different of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (6.67%), Stonepine Capital Management LLC (5.62%), Nantahala Capital Management LLC (3.86%), BlackRock Inc. (1.96%), Millennium Management LLC (1.39%) and 1492 Capital Management LLC (1.25%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.

Which major investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Stonepine Capital Management LLC, Fosun International Ltd, Foresite Capital Management II LLC and Essex Investment Management Co. LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.

Which major investors are buying BioDelivery Sciences International stock?

BDSI stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Millennium Management LLC, Pura Vida Investments LLC, 1492 Capital Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., Penn Capital Management Co. Inc. and BlackRock Inc.. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $4.82.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $341.30 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  433 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  678
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by Staff

Featured Article: Tariff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel